Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Income towards Parent Company: 2010-2018

Historic Income towards Parent Company for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$14.4 million.

  • EyePoint Pharmaceuticals' Income towards Parent Company fell 139.24% to -$14.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$34.6 million, marking a year-over-year decrease of 99.88%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.64% down from last year.
  • Latest data reveals that EyePoint Pharmaceuticals reported Income towards Parent Company of -$14.4 million as of Q3 2018, which was down 46.89% from -$9.8 million recorded in Q2 2018.
  • EyePoint Pharmaceuticals' Income towards Parent Company's 5-year high stood at $20.6 million during Q3 2014, with a 5-year trough of -$14.4 million in Q3 2018.
  • In the last 3 years, EyePoint Pharmaceuticals' Income towards Parent Company had a median value of -$6.0 million in 2017 and averaged -$6.4 million.
  • Per our database at Business Quant, EyePoint Pharmaceuticals' Income towards Parent Company spiked by 657.80% in 2014 and then slumped by 8,568.66% in 2017.
  • Over the past 5 years, EyePoint Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$4.1 million in 2014, then dropped by 27.26% to -$5.2 million in 2015, then spiked by 98.71% to -$67,000 in 2016, then tumbled by 8,568.66% to -$5.8 million in 2017, then crashed by 139.24% to -$14.4 million in 2018.
  • Its last three reported values are -$14.4 million in Q3 2018, -$9.8 million for Q2 2018, and -$4.7 million during Q1 2018.